A Clinical Model to Predict the Occurrence of Select High-risk Infections in the First Year Following Heart Transplantation.

IF 1.9 Q3 TRANSPLANTATION
Transplantation Direct Pub Date : 2023-11-02 eCollection Date: 2023-12-01 DOI:10.1097/TXD.0000000000001542
Whitney A Perry, Jennifer K Chow, Jason Nelson, David M Kent, David R Snydman
{"title":"A Clinical Model to Predict the Occurrence of Select High-risk Infections in the First Year Following Heart Transplantation.","authors":"Whitney A Perry, Jennifer K Chow, Jason Nelson, David M Kent, David R Snydman","doi":"10.1097/TXD.0000000000001542","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Invasive infection remains a dangerous complication of heart transplantation (HT). No objectively defined set of clinical risk factors has been established to reliably predict infection in HT. The aim of this study was to develop a clinical prediction model for use at 1 mo post-HT to predict serious infection by 1 y.</p><p><strong>Methods: </strong>A retrospective cohort study of HT recipients (2000-2018) was performed. The composite endpoint included cytomegalovirus (CMV), herpes simplex or varicella zoster virus infection, blood stream infection, invasive fungal, or nocardial infection occurring 1 mo to 1 y post-HT. A least absolute shrinkage and selection operator regression model was constructed using 10 candidate variables. A concordance statistic, calibration curve, and mean calibration error were calculated. A scoring system was derived for ease of clinical application.</p><p><strong>Results: </strong>Three hundred seventy-five patients were analyzed; 93 patients experienced an outcome event. All variables remained in the final model: aged 55 y or above, history of diabetes, need for renal replacement therapy in first month, CMV risk derived from donor and recipient serology, use of induction and/or early lymphodepleting therapy in the first month, use of trimethoprim-sulfamethoxazole prophylaxis at 1 mo, lymphocyte count under 0.75 × 10<sup>3</sup>cells/µL at 1 mo, and inpatient status at 1 mo. Good discrimination (C-index 0.80) and calibration (mean absolute calibration error 3.6%) were demonstrated.</p><p><strong>Conclusion: </strong>This model synthesizes multiple highly relevant clinical parameters, available at 1 mo post-HT, into a unified, objective, and clinically useful prediction tool for occurrence of serious infection by 1 y post-HT.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 12","pages":"e1542"},"PeriodicalIF":1.9000,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624471/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation Direct","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/TXD.0000000000001542","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Invasive infection remains a dangerous complication of heart transplantation (HT). No objectively defined set of clinical risk factors has been established to reliably predict infection in HT. The aim of this study was to develop a clinical prediction model for use at 1 mo post-HT to predict serious infection by 1 y.

Methods: A retrospective cohort study of HT recipients (2000-2018) was performed. The composite endpoint included cytomegalovirus (CMV), herpes simplex or varicella zoster virus infection, blood stream infection, invasive fungal, or nocardial infection occurring 1 mo to 1 y post-HT. A least absolute shrinkage and selection operator regression model was constructed using 10 candidate variables. A concordance statistic, calibration curve, and mean calibration error were calculated. A scoring system was derived for ease of clinical application.

Results: Three hundred seventy-five patients were analyzed; 93 patients experienced an outcome event. All variables remained in the final model: aged 55 y or above, history of diabetes, need for renal replacement therapy in first month, CMV risk derived from donor and recipient serology, use of induction and/or early lymphodepleting therapy in the first month, use of trimethoprim-sulfamethoxazole prophylaxis at 1 mo, lymphocyte count under 0.75 × 103cells/µL at 1 mo, and inpatient status at 1 mo. Good discrimination (C-index 0.80) and calibration (mean absolute calibration error 3.6%) were demonstrated.

Conclusion: This model synthesizes multiple highly relevant clinical parameters, available at 1 mo post-HT, into a unified, objective, and clinically useful prediction tool for occurrence of serious infection by 1 y post-HT.

Abstract Image

Abstract Image

Abstract Image

预测心脏移植术后第一年选择高危感染发生率的临床模型。
背景:侵袭性感染仍然是心脏移植(HT)的一种危险并发症。尚未建立一组客观定义的临床风险因素来可靠预测HT感染。本研究的目的是开发一个临床预测模型,用于HT后1个月预测1年前的严重感染。方法:对HT受试者(2000-2018)进行回顾性队列研究。复合终点包括HT后1个月至1年发生的巨细胞病毒(CMV)、单纯疱疹或水痘-带状疱疹病毒感染、血流感染、侵袭性真菌或心外膜感染。使用10个候选变量构建了最小绝对收缩和选择算子回归模型。计算了一致性统计量、校准曲线和平均校准误差。为了便于临床应用,推导了评分系统。结果:对375例患者进行了分析;93名患者经历了一次结果事件。所有变量均保留在最终模型中:年龄55岁或以上,糖尿病史,第一个月是否需要肾脏替代治疗,供体和受体血清学的CMV风险,在第一个月使用诱导和/或早期淋巴消耗治疗,在1个月时使用甲氧嘧啶-磺胺甲恶唑预防,淋巴细胞计数低于0.75 × 1个月时为103个细胞/µL,1个月为住院状态。显示出良好的辨别力(C指数0.80)和校准(平均绝对校准误差3.6%)。结论:该模型将HT后1个月可用的多个高度相关的临床参数综合为一个统一、客观和临床有用的预测工具,用于预测HT后1年严重感染的发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transplantation Direct
Transplantation Direct TRANSPLANTATION-
CiteScore
3.40
自引率
4.30%
发文量
193
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信